Cancer.NetCancer.Net
Image
Cancer.Net Site Search
 
 
Quick Links
 
 
Other ASCO websites
ASCO 
Journal of Clinical Oncology 
Journal of Oncology Practice 
The ASCO Cancer Foundation 
ASCO Press Center 

Understanding Survival Statistics: Guiding Prognosis and Evaluating Treatment  

This section has been reviewed and approved by the Cancer.Net Editorial Board,  06/08

When people are diagnosed with cancer, one of the first things they may want to know is their chance of survival and recovery. They may also want to know how this information can help them to choose between different treatment options. Understanding survival statistics becomes extremely important, yet it can also be confusing. Survival statistics can be used to establish a patient’s prognosis and can help determine the treatment options.

Five-year relative survival rates

Survival statistics, usually given as rates, describe the percentage of people with a certain stage and/or type of cancer who will be alive a certain time period after the cancer is detected. Survival rates can be given for any length of time. Cancer statistics are usually given as a five-year relative survival rate; this describes the percentage of people with cancer who will be alive five years after diagnosis, excluding those who die from other diseases. For example, the five-year relative survival rate for cervical cancer is 72%, which means that 72% of women with cervical cancer will still be living five years after diagnosis.

Survival statistics are usually calculated for specific cancer stages (the stage is an indication of if and how far the cancer has spread) as survival statistics can vary by stage. For example, as of 2008, the five-year relative survival rate for early-stage bladder cancer is 95%. If, however, the cancer is diagnosed at a later stage, the five-year relative survival rate is 16%. Survival statistics for all stages of a cancer combined are referred to as an overall rate, such as the overall five-year relative survival rate for all prostate cancer cases which, regardless of stage, is 98%.

Disease-free and progression-free survival

Five-year relative survival rates include all people who are alive five years after a cancer diagnosis, including those who are in remission (temporary or permanent absence of disease) or still being treated. Disease-free survival statistics and progression-free survival statistics are more specific survival statistics that are often used in evaluating cancer treatments.

  • Disease-free survival rates refer only to the percentage of people who experience a complete remission after finishing treatment.

  • Progression-free survival rates describe the percentage of people who do not experience any new tumor growth or cancer spread during or after treatment, including those whose disease has either completely or partially responded to treatment, or those whose disease is stable (the cancer is still present but not advancing).

Survival statistics and the concept of “cure”

In medicine, a disease is considered cured when it’s been successfully treated and does not return. The concept of “cure” is difficult to apply to cancer because undetected cancer cells can sometimes remain in the body after treatment, causing the cancer to return at a later time (referred to as a recurrence or relapse). Many cancers are considered “cured” when there is no cancer detected five years after diagnosis. However, recurrence after five years is still possible.

Predicting prognosis

Among the first questions often asked when a person is diagnosed with cancer is whether the cancer can be treated successfully. This is called a prognosis—the likely course and outcome of the cancer and the chances of recovery. Doctors use survival statistics to make predictions about prognosis. For example, a man diagnosed with testicular cancer may be said to have a favorable prognosis, as the overall five-year relative survival rate for testicular cancer is 95%.

Similar to survival statistics, prognosis also depends on the stage of the cancer at diagnosis—how early the cancer is detected and if or how far it has spread. For example, if detected early, the five-year relative survival rate for colorectal cancer is greater than 90%. For advanced stage colorectal cancer that has spread to distant parts of the body, the five-year relative survival rate is about 10%.

Points to remember

  • Statistics are estimates that describe trends in large numbers of people. Statistics cannot be used to predict what will actually happen to an individual.

  • Survival statistics for different cancer types, stages of cancer, age groups, or time periods can vary dramatically. People are encouraged to ask their doctor for the most appropriate statistics based on their individual medical condition.

  • As with any medical information, ask your doctor for clarification if cancer-related statistics seem unclear.

Evaluating treatment options

Five-year relative survival rates are commonly used as a way to evaluate and compare different treatment options. Although someone who has survived five years after a cancer diagnosis is not necessarily “cured,” the five-year relative survival statistic is considered a good indication that the cancer is responding to treatment and that the treatment is successfully extending the life of the individual with cancer. Survival statistics help doctors determine which treatments provide the most benefit to people with cancer, and whether the benefits outweigh any risks (such as unpleasant side effects) associated with the treatment.

Points to remember

  • Because five-year survival statistics are based on patients who were treated at least five years ago, they may not reflect the most recent advances in treatment.

  • Although survival statistics provide useful information when deciding among treatment options, they should be used as only one factor in a comprehensive treatment plan designed by a doctor who is familiar with a person’s individual situation.

For More Information

Understanding Statistics on Incidence, Prevalence, and Mortality

Risk Factors





Last Updated: June 13, 2008

 Options
 Printer-Friendly

 E-mail this page




About Us  |  Privacy Policy Contact Us  |  Terms & Conditions  | Linking InformationSponsorship Information
 
© 2006-2009 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.